Thyroid cancer patients are diagnosed and evaluated by multiple physicians across many different institutions. As a result, vital communication is lost between physicians, thus hindering their ability to provide the best quality of care. Inadequate clinical communication can result in incorrect diagnoses, inappropriate surgery, incorrect disease stratification, and pathologic interpretation. Research has shown that good […]
The recent rise in the incidence of thyroid cancer may be due to the increase in identification of low-risk papillary thyroid cancers through the use of ultrasound and/or biopsy. Most of these small, low-risk thyroid cancers (tumors < 1 cm) do not grow or grow very slowly. A new management strategy for low-risk thyroid cancers, […]
Anaplastic thyroid cancer is a very aggressive and rare form of thyroid cancer. The US Food and Drug Administration has approved the use of Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) administered together to treat anaplastic thyroid cancer that cannot be surgically removed or has spread to other locations in the body, and is BRAF V600E […]
We are pleased to announce that an article featuring the Thyroid Care Collaborative (TCC) has been published in the International Journal of Endocrine Oncology. The article describes all of the ways in which the TCC can be used a method of facilitating the multidisciplinary management of thyroid cancer.